10 Best Low Cost Stocks to Buy According to Billionaires

4. Amicus Therapeutics, Inc. (NASDAQ:FOLD)

No. of Billionaires: 11

Total Value of Billionaire Holdings: $0.34 Billion

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a biotechnology company specializing in rare and orphan diseases, particularly lysosomal storage disorders. The key products and pipeline candidates focus on precision therapies, such as Galafold for Fabry disease and AT-GAA for Pompe disease. Headquartered in Pennsylvania, the company competes with tough players like BioMarin and Sanofi. However, the patient-centric approach and innovative science in enzyme replacement and gene therapy offer a competitive edge for the company. Specifically, the targeted focus on high-unmet-need populations, supported by regulatory incentives for rare disease innovation, makes the company stand out among other competitors in the industry. It is one of the best cheap stocks to buy.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) draws support from 11 billionaires with $0.34 billion in holdings. 2024 has been a favorable year for the company, with full-year revenue reaching $528 million, a 32% increase compared to the previous year. The leading performer, Galafold, achieved revenue of $458 million, while Pombiliti and Opfolda reached over $70 million globally in 2024. The company’s guidance for 2025 involves a revenue growth of 17% to 24%. Contributors to this growth are a 10% to 15% projected growth in Galafold revenue and a 65% to 85% growth in Pombiliti + Opfolda.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) features 40 hedge fund portfolios at the end of Q4 2024, reflecting strong institutional support for the stock. Holding a Buy rating from analysts, FOLD has a remarkable upside of 126.67%, one of the highest on our list of valuable cheap stocks.